COMPARE · Data as of August 21, 2026
BHC vs HIMS
Verdict: Side-by-side breakdown using the Bull Rankings model. BHC scored 71.3, HIMS scored 39.3 — BHC leads.
Compare another set
BHC
Bausch Health Companies Inc.
71.3
$6.44 · $2.4B
fundamentals as of
Score gap
32.0
BHC leads
HIMS
Hims & Hers Health, Inc.
39.3
$31.13 · $7.3B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestBHC0.2x
- Fastest growthHIMS+28.0%
- Highest qualityBHC63 / 100
- Largest discount to fair valueBHC-86%
Side by side · every name on one set of axes
Growth against the P/S multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
BHC
stronger →← stronger
HIMS
63
Qualityreturns · margins · balance sheet
23
64
Growthrevenue & earnings expansion
93
90
Valuevaluation vs sector peers
29
BHC is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
BHC
HIMS
$1.4bC+
FCF
$62mC-
+10.1%B
Rev
+28.0%A-
—
D/E
4.77D
0.2xA
P/S
2.8xB+
0.01A
PEG
2.15C
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
BHC
HIMS
86% below
Price vs fair valuelower is cheaper
777% above
decline
Growth the price implies10-yr FCF · lower = less priced in
>60%/yr
+706%
1-yr DCF upside
-91%
+625%
5-yr DCF upside
-89%
+526%
10-yr DCF upside
-84%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
BHC
HIMS
Why this score
- Diluting shareholders
The companies
BHCBausch Health Companies Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $2.4b. 19% off the 52-week high of $8.00. Revenue growing +10%, comfortably above the S&P median. PEG 0.01 — paying under fair value for the growth rate. 5 sell-side analysts publish a mean 1-yr target of $7.50 (implying +16% upside).
Moat
ROE 62% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -10.1%) — path to GAAP profitability is the core thesis risk. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
HIMSHims & Hers Health, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $7.3b. Down 52% from 52-week high of $65.30 — deep drawdown territory. Revenue growing +28% — in hypergrowth territory. 13 sell-side analysts rate this a Hold with a mean 1-yr target of $30.85 (implying -1% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 4.77 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Currently unprofitable (margin -5.5%) — path to GAAP profitability is the core thesis risk. Down 52% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where BHC and HIMS diverge
On the headline score the gap is 32.0 points in favor of BHC. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- ValueBHC 90.4 · HIMS 28.8BHC +61.6
- QualityBHC 62.9 · HIMS 22.7BHC +40.2
- GrowthBHC 63.7 · HIMS 92.8HIMS +29.1
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.